Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 9, 2009
JNCI Journal of the National Cancer Institute 2009 101(12):844-845; doi:10.1093/jnci/djp170
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/12/844    most recent
djp170v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

NEWS

New Trial Data Do Not End the PSA Screening Debate

Brian Vastag

The first 150 words of the full text of this article appear below.

To screen or not to screen?

For prostate cancer, that is still the question, despite the release this spring of mortality data from two large trials that asked whether prostate-specific antigen (PSA) testing reduces the risk of dying from prostate cancer. In the United States, the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial found no mortality benefit for PSA screening after 7–10 years. Across the Atlantic, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 20% mortality benefit after 10 years of PSA screening. Both studies were published in the March 26, 2009, New England Journal of Medicine.

The data generated conflicting responses. The American Cancer Society (ACS) continued to not recommend routine screening. Instead, the ACS endorses shared decision making, with men and their physicians discussing the pros and cons of PSA screening before deciding on the blood test. The American Urological Association, . . . [Full Text of this Article]

First Draft

European Trial

Moving Ahead


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?